Gang Yan
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
In vivo CRISPR screening identifies metastasis suppressors in triple-negative breast cancer.
Journal: Nature communications
Published: November 05, 2025
Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma.
Journal: Molecular cancer
Published: July 02, 2025
Author Correction: Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs.
Journal: NPJ precision oncology
Published: July 08, 2024
Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer.
Journal: Molecular cancer
Published: September 08, 2023
Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs.
Journal: NPJ precision oncology
Published: August 23, 2023
Combined in vitro/in vivo genome-wide CRISPR screens in triple negative breast cancer identify cancer stemness regulators in paclitaxel resistance.
Journal: Oncogenesis
Published: March 28, 2023
In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy.
Journal: Nature communications
Published: May 14, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026